Log in to search using one of your social media accounts:

 

Following regulatory win, GSK & Innoviva tout data for once-daily triple-med inhaler
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) notched a win this week after the FDA approved its once-daily, triple combination therapy for the treatment of chronic obstructive pulmonary disease. Last week, an EU agency recommended the inhaler’s approval. Now, the companies are touting results from a late-stage trial of Trelegy Ellipta, which is composed of an inhaled corticosteroid, a long-acting muscarinic antagonist and a long-acting beta agonist. Get the full story at our sister site, Drug Delivery Business News. The post Following regulatory win, GSK & Innoviva tout data f...
Source: Mass Device - September 20, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat GlaxoSmithKline plc Innoviva Source Type: news

Boston Scientific touts 3-year Alair follow-up study results
Boston Scientific (NYSE:BSX) today released 3-year follow-up cohort results from the post-FDA approved PAS2 clinical trial of its Alair system designed for bronchial thermoplasty to treat severe persistent asthma, touting reduced severe asthma attacks, hospitalizations and ER visits. Results from the trial were recently published in the European Respiratory Journal, the Marlborough, Mass.-based company said. The PAS2 trial is an open-label study which enrolled patients at 27 North American centers, with 95% of the recruited patients considered severe asthmatics. Boston Scientific said that data from the cohort co...
Source: Mass Device - September 18, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Respiratory Boston Scientific Source Type: news

GSK ’s triple-med COPD inhaler wins recommendation for approval in EU
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said today that a European Medicines Agency panel recommended marketing authorization for the Trelegy Ellipta triple-combination inhaler for adults with COPD. The device uses fluticasone furoate, umeclidinium and vilanterol to help adults with COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist. It’s also the first once-daily single inhaler triple therapy to win a positive opinion by the Committee for Medicinal Products for Human Use, the companies reported. Get the full story at our sister...
Source: Mass Device - September 15, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat GlaxoSmithKline plc Innoviva Source Type: news

Interventions for treating tuberculous pericarditis
(Liverpool School of Tropical Medicine) Researchers from South Africa and Canada have carried out a Cochrane review update to assess the safety and effectiveness of corticosteroids for treating tuberculous pericarditis. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 14, 2017 Category: Infectious Diseases Source Type: news

Expensive drug driving up Medicare expenditures without evidence of greater efficacy
(Oregon State University) Medicare spent more than $1 billion over a five-year period on a high-priced drug that has not been proven more effective for a collection of inflammatory conditions than much less expensive corticosteroids. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 11, 2017 Category: International Medicine & Public Health Source Type: news

Oral Corticosteroids of No Benefit in Nonasthmatic Adults with Lower Respiratory Tract Infection (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH Oral corticosteroids offer no benefit to nonasthmatic adults with acute lower respiratory tract infection, according to a placebo-controlled trial in JAMA … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 23, 2017 Category: Primary Care Source Type: news

Oral Corticosteroids No Benefit for LRI in Non - Asthmatic Adults
No decrease in cough duration, severity for adults without asthma with lower respiratory tract symptom (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - August 23, 2017 Category: Respiratory Medicine Tags: Family Medicine, Infections, Internal Medicine, Emergency Medicine, Nursing, ENT, Pharmacy, Pulmonology, Journal, Source Type: news

Corticosteroid injection may offer little advantage for Morton ’s neuroma patients treated with local anesthetic
According to a study published online in the journal Foot & Ankle International, corticosteroid injection plus local anesthetic may not be superior to local anesthetic alone in terms of pain and function for patients with Morton’s neuroma.  (Source: Orthogate - Latest News)
Source: Orthogate - Latest News - August 20, 2017 Category: Orthopaedics Tags: Featured Editors Choice News Source Type: news

Drug safety update: Corticosteroids: rare risk of central serous chorioretinopathy
The Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a drug safety update ...... (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - August 17, 2017 Category: Drugs & Pharmacology Source Type: news

Laser in the management of burn scars
Burn scars are associated with significant morbidity ranging from contractures, pruritus, and disfigurement to psychosocial impairment. Traditional therapies include silicone gel, compression garments, corticosteroid injections, massage therapy, and surgical procedures, however, newer and advanced therapies for the treatment of burn scars have been developed. Lasers, specifically ablative fractional lasers, show potential for the treatment of burn scars. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 8, 2017 Category: Consumer Health News Source Type: news

Oral Corticosteroids Tied to Serious Adverse Events in IgA Nephropathy (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM Oral corticosteroids for patients with immunoglobulin A nephropathy are associated with increased risk for serious infections, a JAMA study finds.Some 260 … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 2, 2017 Category: Primary Care Source Type: news

Infection Concern Halts Kidney Disease Drug Trial
Doctors should weigh risks, benefits related to corticosteroid use, study suggests (Source: WebMD Health)
Source: WebMD Health - August 1, 2017 Category: Consumer Health News Source Type: news

Drug for Kidney Disease Tied to Infection Risk
Doctors should weigh risks, benefits related to corticosteroid use, study suggests Source: HealthDay Related MedlinePlus Pages: Kidney Diseases (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 1, 2017 Category: Consumer Health News Source Type: news

Methylprednisolone for Kidney Disease Tied to Infection Risk
TUESDAY, Aug. 1, 2017 -- A drug used for some cases of kidney disease can raise the risk of serious infections, researchers say. A clinical trial was stopped early when researchers discovered that patients on the drug -- a corticosteroid called... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 1, 2017 Category: General Medicine Source Type: news

Fear Keeps Many Eczema Patients From Using Steroid Creams Fear Keeps Many Eczema Patients From Using Steroid Creams
Many people with eczema may avoid creams and ointments that can help ease symptoms like itching and inflammation because they ’ re afraid to try topical corticosteroids, a recent study suggests.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 28, 2017 Category: Allergy & Immunology Tags: Dermatology News Source Type: news

NICE backs biologic for treating condition that can cause blindness
A monoclonal antibody and a biodegradable corticosteroid implant have been approved for use by the NHS in England and Wales to treat an inflammatory eye condition that can lead to blindness. (Source: Nursing Times)
Source: Nursing Times - July 28, 2017 Category: Nursing Source Type: news

Fear keeps many eczema patients from using steroid creams
(Reuters Health) - Many people with eczema, a common skin disease, may avoid creams and ointments that can help ease symptoms like itching and inflammation because they ’re afraid to try topical corticosteroids, a recent study suggests. (Source: Reuters: Health)
Source: Reuters: Health - July 26, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Clearside Biomedical launches Phase II diabetic macular edema trial
Clearside Biomedical (NSDQ:CLSD) said today that it enrolled the first patient in a Phase II clinical trial of CLS-TA in patients with diabetic macular edema. The trial plans to evaluate Clearside’s suspension formulation of a corticosteroid, triamcinolone acetonide, as a suprachoroidal injection in combination with an intravitreal injection of Eylea, an anti-VEGF agent. Get the full story at our sister site, Drug Delivery Business News. The post Clearside Biomedical launches Phase II diabetic macular edema trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 12, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Optical/Ophthalmic Pharmaceuticals Wall Street Beat Clearside Biomedical Source Type: news

​Ocular Therapeutix faces fraud allegations as FDA rejects eye drug
Bedford eye care biotech Ocular Therapeutix saw its share price plummet on Wednesday after the FDA rejected its lead drug for the second time. To make matters worse, the company and its top executives are now facing fraud allegations in federal court. Ocular (Nasdaq: OCUL) said after markets closed on Tuesday that the FDA had denied its application for Dextenza, a tiny insert that is placed in the eye and delivers a corticosteroid to treat pain following surgical procedures. Regulators cited manufacturing… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 12, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Better Vision-related QOL With Fluocinolone Acetonide Implant for Uveitis Better Vision-related QOL With Fluocinolone Acetonide Implant for Uveitis
Treatment of noninfectious uveitis with fluocinolone acetonide implants is associated with better vision-related quality of life, compared with systemic corticosteroid therapy, according to results from the MUST research group.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - July 5, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news

School's in for asthma medication adherence
(Children's National Health System) Stephen J. Teach, M.D., M.P.H., and colleagues tried to reduce missed doses of daily medications, improve asthma control and tamp down on schoolchildren's asthma attacks by outsourcing morning delivery of inhaled corticosteroids to the school nurse. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 3, 2017 Category: International Medicine & Public Health Source Type: news

Drug cocktail may help prevent sepsis shock, death
Researchers have found that a drug cocktail of vitamin C, corticosteroids and thiamine may help prevent progressive organ failure caused by sepsis. (Source: Health News - UPI.com)
Source: Health News - UPI.com - June 26, 2017 Category: Consumer Health News Source Type: news

Readily available drug cocktail may help prevent sepsis shock and death
(Elsevier) Even in advanced medical settings, sepsis is still very dangerous and accounts for over 400,000 deaths annually in the US alone. While new drugs are in development, a group of researchers has determined that a combination of intravenous vitamin C, corticosteroids (a steroid), and thiamine (vitamin B) may be effective in preventing progressive organ dysfunction and reducing the number of deaths from severe sepsis and septic shock. Their findings are published in the June issue of CHEST. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 26, 2017 Category: International Medicine & Public Health Source Type: news

Readily available drug cocktail can help prevent sepsis shock and death
(Elsevier) Even in advanced medical settings, sepsis is still very dangerous and accounts for over 400,000 deaths annually in the US alone. While new drugs are in development, a group of researchers has determined that a combination of intravenous vitamin C, corticosteroids (a steroid), and thiamine (vitamin B) may be effective in preventing progressive organ dysfunction and reducing the number of deaths from severe sepsis and septic shock. Their findings are published in the June issue of CHEST. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - June 26, 2017 Category: International Medicine & Public Health Source Type: news

Thinking Machines: From Magic to Normal
“Technology made large populations possible; large populations now make technology indispensable.”                – Joseph Krutch (Writer)Since the 19th century, we have undergone several stages of machine revolutions.The first stage was mechanisation. The advent of modern production methods eased and sped up manufacturing, massively increasing output and ushering in the Industrial Revolution.The late 60s brought the age of the working computer. In 1967, an IBM infomercial, ‘The Paperwork Explosion’, predicted a dystopi...
Source: EyeForPharma - June 22, 2017 Category: Pharmaceuticals Authors: Jacqui Sanders Source Type: news

Thinking Machines: From Magic to Normal
“Technology made large populations possible; large populations now make technology indispensable.”                – Joseph Krutch (Writer)Since the 19th century, we have undergone several stages of machine revolutions.The first stage was mechanisation. The advent of modern production methods eased and sped up manufacturing, massively increasing output and ushering in the Industrial Revolution.The late 60s brought the age of the working computer. In 1967, an IBM infomercial, ‘The Paperwork Explosion’, predicted a dystopi...
Source: EyeForPharma - June 22, 2017 Category: Pharmaceuticals Authors: Jacqui Sanders Source Type: news

Thinking Machines: From Magic to Normal
“Technology made large populations possible; large populations now make technology indispensable.”                – Joseph Krutch (Writer)Since the 19th century, we have undergone several stages of machine revolutions.The first stage was mechanisation. The advent of modern production methods eased and sped up manufacturing, massively increasing output and ushering in the Industrial Revolution.The late 60s brought the age of the working computer. In 1967, an IBM infomercial, ‘The Paperwork Explosion’, predicted a dystopi...
Source: EyeForPharma - June 22, 2017 Category: Pharmaceuticals Authors: Jacqui Sanders Source Type: news

Boston Scientific launches Alair asthma treatment in India
Boston Scientific (NYSE:BSX) has launched its Alair bronchial thermoplasty therapy in India, according to an India Blooms report. The device won clearance in the country with indications for treating severe, persistent, drug-resistant asthma in adult patients who’s asthma is not well controlled with inhaled corticosteroids and long acting beta antagonists. Marlborough, Mass.-based Boston Scientific’s Alair bronchial thermoplasty treatment uses a bronchoscope to deliver radiofrequency energy to reduce the amount of excess smooth muscle tissue in the airways. “There are over 18 million estimated a...
Source: Mass Device - June 13, 2017 Category: Medical Devices Authors: Fink Densford Tags: Regulatory/Compliance Respiratory Boston Scientific Source Type: news

Anika launches late-stage supplemental Cingal study
Anika Therapeutics (NSDQ:ANIK) said yesterday that it enrolled the 1st patient in a supplemental Phase III efficacy and safety trial of its Cingal hyaluronic acid-corticosteroid combination viscosupplement. The Bedford, Mass.-bsaed company is evaluating Cingal as a treatment for osteoarthritis-related knee pain. Get the full story at our sister site, Drug Delivery Business News. The post Anika launches late-stage supplemental Cingal study appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - May 26, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Orthopedics Pharmaceuticals Regenerative Medicine Wall Street Beat Anika Therapeutics Inc. Source Type: news

New medicine shows potential to reduce oral steroid use in severe asthma patients
(McMaster University) The results of the trial, published this week in the New England Journal of Medicine, demonstrate that patients treated with a potential new medicine and antibody, called benralizumab, were more than four times likely to reduce their usage of oral corticosteroids than those taking a placebo. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 25, 2017 Category: International Medicine & Public Health Source Type: news

Boston Scientific ’ s post-approval Alair study shows long-term asthma improvement
Patients treated with the Alair device made by Boston Scientific (NYSE:BSX) showed long-term improvement in controlling their asthma, according to a post-approval study released today at the annual meeting of the American Thoracic Society in Washington. The Alair bronchial thermoplasty treatment uses a bronchoscope to deliver radiofrequency energy to reduce the amount of excess smooth muscle tissue in the airways. Boston acquired the technology when it paid $194 million in cash for Asthmatx in 2010, shortly after that company won 510(k) clearance from the FDA for Alair. The deal also included some $250 million in pote...
Source: Mass Device - May 24, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Respiratory Wall Street Beat Boston Scientific Source Type: news

Novartis ’ Ultibro Breezhaler tops corticosteroid for COPD in head-to-head study
Novartis (NYSE:NVS) said today that a new analysis of its head-to-head Flame trial showed that inhaled corticosteroids may not be necessary in some chronic obstructive pulmonary disease patients with high blood eosiophil counts. The data demonstrated that the company’s Ultibro Breezhaler provided better or similar benefits compared to Seretide, an inhaled corticosteroid, in COPD patients regardless of eosiophil count. These results contrast with previous work suggesting better outcomes with inhaled corticosteroids for patients with high eosinophil counts. Get the full story at our sister site, Drug Delivery Business ...
Source: Mass Device - May 23, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Novartis Source Type: news

Anika touts Phase III data for Cingal knee therapy
Anika Therapeutics (NSDQ:ANIK) touted data today from a Phase III trial for its Cingal hyaluronic acid-corticosteroid combination viscosupplement as a treatment for osteoarthritis-related knee pain. The data showed that treatment with Cingal yielded better immediate and short-term pain relief compared to hyaluronic acid alone and better pain and stiffness relief through 26 weeks compared to saline. The data was published in the journal Cartilage.  Get the full story at our sister site, Drug Delivery Business News. The post Anika touts Phase III data for Cingal knee therapy appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - May 22, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Food & Drug Administration (FDA) Pain Management Pharmaceuticals Regulatory/Compliance Wall Street Beat Anika Therapeutics Inc. Source Type: news

Triple-combo inhaler for COPD wins recommendation for approval in EU
Chiesi Group said today that the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended that the EMA approve its extra-fine triple combination inhaler for the treatment of chronic obstructive pulmonary disease. The Trimbow device combines an inhaled corticosteroid, a long-acting beta2-agonist and a long-acting muscarinic antagonist. The healthcare group said it is the 1st time the extra-fine triple therapy has been available in a single inhaler. Get the full story at our sister site, Drug Delivery Business News. The post Triple-combo inhaler for COPD wins recommendation for approval in...
Source: Mass Device - May 22, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat chiesigroup Source Type: news

What Bronchodilator Options Do We Have for COPD? What Bronchodilator Options Do We Have for COPD?
Are fixed combinations better than monotherapy? How should you add a corticosteroid to the regimen? Dr Gross discusses a new meta-analysis designed to clarify these issues.Medscape Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 19, 2017 Category: Consumer Health News Tags: Pulmonary Medicine Viewpoint Source Type: news

Acid-Suppressing Drugs May Blunt Corticosteroid Response in Asthma Acid-Suppressing Drugs May Blunt Corticosteroid Response in Asthma
Acid-suppression medications are associated with changes in the airway microbiome in patients with asthma, and these changes may affect corticosteroid response, new research suggests.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 19, 2017 Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news

Mepolizumab helps patients with refractory Churg-Strauss syndrome
Mepolizumab, an anti-IL5 monoclonal antibody, increased remission rates, cut exacerbations in half and reduced the need for ongoing corticosteroid therapy in patients with refractory cases of the rare autoimmune disease Churg-Strauss Syndrome, according to research. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 17, 2017 Category: Science Source Type: news

Intra-Articular Corticosteroids Show No Benefit in Knee Osteoarthritis (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM Intra-articular triamcinolone does not help relieve knee pain in adults with osteoarthritis — and might even lead … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 17, 2017 Category: Primary Care Source Type: news

Medical News Today: Knee osteoarthritis: Steroid injections offer no benefit, study suggests
Corticosteroid injections do not ease pain for patients with knee osteoarthritis and may even lead to greater loss of cartilage, new research suggests. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 16, 2017 Category: Consumer Health News Tags: Arthritis / Rheumatology Source Type: news

Steroid Shots Do Little for Knee Pain of Arthritis
Corticosteroid injections were no more effective than a placebo in relieving pain or stiffness or improving the ability to walk. (Source: NYT Health)
Source: NYT Health - May 16, 2017 Category: Consumer Health News Authors: NICHOLAS BAKALAR Tags: Knees Placebos Steroids Source Type: news

Topical Corticosteroids
Title: Topical CorticosteroidsCategory: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 5/12/2017 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - May 12, 2017 Category: Dermatology Source Type: news

Systemic Therapy for Uveitis Provides Better Long-term Visual Acuity Systemic Therapy for Uveitis Provides Better Long-term Visual Acuity
Systemic corticosteroids supplemented by immunosuppression provides better long-term visual acuity than intravitreous fluocinalone in patients with uveitis, according to results from the MUST trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 10, 2017 Category: Allergy & Immunology Tags: Ophthalmology News Source Type: news

No Benefit From Corticosteroids for Acute, Simple Urticaria No Benefit From Corticosteroids for Acute, Simple Urticaria
Corticosteroids do not speed relief for patients presenting to the emergency department (ED) with acute urticaria, according to a new randomized trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 10, 2017 Category: Allergy & Immunology Tags: Dermatology News Source Type: news

Sanofi CEPiA Product List
Sanofi CEPiA provides a wide range of products, including active pharmaceutical ingredients (API), corticosteroids and hormones, francopia, prostaglandins, and biotechnologies. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 10, 2017 Category: Pharmaceuticals Source Type: news

Systemic therapy beats Bausch & Lomb implant in NIH uveitis study
Systemic therapy of corticosteroids and immunosuppressants better preserved vision in patients with uveitis compared to Bausch & Lomb‘s long-lasting corticosteroid intraocular implant in a clinical trial supported by the National Eye Institute, a branch of the National Institutes of Health. In 7 years, visual acuity remained stable in patients receiving systemic therapy and declined by an average of 1 line on an eye chart among patients with the implant, according to the study. Get the full story at our sister site, Drug Delivery Business News. The post Systemic therapy beats Bausch & Lomb implant in NIH uvei...
Source: Mass Device - May 8, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Implants Optical/Ophthalmic Pharmaceuticals Wall Street Beat Bausch Lomb National Institutes of Health (NIH) Source Type: news

Systemic Tx Offers Better Outcomes in Severe Uveitis (CME/CE)
(MedPage Today) -- Better visual acuity with long-term corticosteroids (Source: MedPage Today Ophthalmology)
Source: MedPage Today Ophthalmology - May 7, 2017 Category: Opthalmology Source Type: news

Systemic therapy outperforms intraocular implant for treating uveitis
Systemic therapy consisting of corticosteroids and immunosuppressants preserved vision of uveitis patients better – and had fewer adverse outcomes – than a long-lasting corticosteroid intraocular implant, according to a clinical trial funded by the National Eye Institute (NEI). After seven years, visual acuity on average remained stable among participants on systemic therapy but declined by an average of si x letters (about one line on an eye chart) among participants who had the implant. NEI is part of the National Institutes of Health. (Source: News from NEI)
Source: News from NEI - May 7, 2017 Category: Opthalmology Authors: haysdc Source Type: news

Short Term Use of Oral Corticosteroids and Related Harms Short Term Use of Oral Corticosteroids and Related Harms
This study examined characteristics of short-term oral corticosteroid prescriptions in the U.S., and their associated risk of adverse events.The BMJ (formerly known as the British Medical Journal) (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 5, 2017 Category: Allergy & Immunology Tags: Internal Medicine Journal Article Source Type: news

Appropriate Selection of Corticosteroids in Treating Asthma and COPD
You're dispatched to the scene of a residential facility for a patient with difficulty breathing. You and your partner arrive to find an elderly male on his living room couch in clear respiratory distress as indicated by tripod positioning with accessory muscle use, pursed lip breathing, and paradoxical chest wall/abdominal movements (positive Hoover sign). Initial impression of your patient reveals he has difficulty speaking due to his increased respiratory effort and explains that recently he's unable to catch his breath. He says he recently ran out of his home DuoNeb (ipratropium bromide/albuterol sulfate) treatments. F...
Source: JEMS Patient Care - May 4, 2017 Category: Emergency Medicine Authors: William Heuser, PharmD, AEMT-CC Tags: Airway & Respiratory Patient Care Source Type: news